Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Hutchmed China Ltd ADR
(NQ:
HCM
)
20.22
+1.28 (+6.76%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
102,711
Open
19.63
Bid (Size)
20.01 (1)
Ask (Size)
20.22 (1)
Prev. Close
18.94
Today's Range
19.63 - 20.34
52wk Range
11.93 - 21.92
Shares Outstanding
871,256,270
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why HUTCHMED Stock Is Moving Higher Friday
July 05, 2024
HUTCHMED announced that its New Drug Application for Tazemetostat for the treatment of relapsed or refractory follicular lymphoma was accepted in China with Priority Review status.
Via
Benzinga
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
July 03, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Performance
YTD
+15.48%
+15.48%
1 Month
+12.77%
+12.77%
3 Month
+19.36%
+19.36%
6 Month
+53.18%
+53.18%
1 Year
+49.56%
+49.56%
More News
Read More
HUTCHMED to Announce 2024 Half-Year Financial Results
June 26, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
June 24, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
June 21, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
June 16, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
June 06, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
June 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
May 23, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
May 17, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
May 16, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
May 13, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
May 13, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
May 09, 2024
Via
Benzinga
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
May 08, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
April 26, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
Via
Talk Markets
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
April 05, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
April 02, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
March 27, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
March 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
Why SurgePays Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
March 13, 2024
Via
Benzinga
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 13, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 13, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.